ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EUDA vs JNJ // EV/EBITDA & P/E VALUATION

EUDA Health Holdings Limited (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: EUDA 1 — JNJ 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EUDA VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EUDA JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 43.90% 67.90% -24.00 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -5.39% 2.97% -8.36 JNJ /fcf-yield <GO>
Operating Margin -36.30% 34.70% -71.00 JNJ /operating-margins <GO>
Net Profit Margin -40.70% 28.50% -69.20 JNJ /net-margins <GO>
Revenue Growth (YoY) 70.00% 6.00% +64.00 EUDA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 59.7 62.1 -2.41 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $46.4M $662.49B -$662.45B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EUDA REV JNJ REV EUDA GROSS % JNJ GROSS % EUDA FCF JNJ FCF
FY 2025 $6.8M $94.19B 43.9% 67.9% -$2.5M $19.70B
FY 2024 $4.0M $88.82B 19.0% 69.1% -$2.1M $19.84B
FY 2023 $3.7M $85.16B — — -$2.9M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EUDA // BETA —
JNJ // BETA 1.08